Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Revenue comparison 10 years later
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Sep 23, 2022 1:00pm
170 Views
Post# 34982324

RE:RE:RE:Revenue comparison 10 years later

RE:RE:RE:Revenue comparison 10 years later
EbbFlow88 wrote: My thoughts exactly. They are certainly buying back here but the volume hasn't been very high so it seems buybacks are muted to save for a deal around the corner. Or they see a bigger market panic event to really put the buybacks to work. 




Note that the shelf prospectus should expire in early 2023 (Jan 23 2023 ?)
I believe this was positioned to take advantage of ATE's 346 chronic drug in South America - which didn't happen for obvious reasons.

I'm going to assume the shelf prospectus gets extended and waits for ATE's 346 acute drug.
Starting Phase 2 - 3rd Molar Extraction ... likely on September 28th - next week.

Don't get me wrong ... the shelf prospectus could find a different purpose - and - maybe Samara isn't interested in ATE's drug for LATAM (anymore) - but - any decisions will be evaluated on its own and against holding out for 346 in LATAM.  IMO.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities